• Halit Çınarka, Gülşah Günlüoğlu, Mustafa Çörtük, Sibel Yurt, Murat Kıyık, Filiz Koşar, Elif Tanrıverdi, Melih Akay Arslan, Kürşad Nuri Baydili, Aysu Sinem Koç, Sedat Altın, and Erdoğan Çetinkaya.
• Department of Pulmonology, University of Health Sciences Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, İstanbul, Turkey
• Turk J Med Sci. 2021 Aug 30; 51 (4): 1624-1630.

Background/AimSARS-CoV-2, a ribonucleic acid coronavirus, rapidly spread worldwide within a short timeframe. Although different antiviral, antiinflammatory, and immunomodulatory drugs are used, current evidence is insufficient as to which drug is more efficient. Our study compared favipiravir and lopinavir/ritonavir (LPV/RTV) therapies in inpatient care for coronavirus disease 2019 (COVID-19) pneumonia.Materials And MethodsDemographic data, test results, treatments, and latest status of patients receiving inpatient COVID-19 pneumonia therapy were recorded. The initial favipiravir and LPV/RTV receiving groups were compared regarding the need for intensive care units (ICU) and mortality. Logistic regression analysis was performed by including variables showing significant differences as a result of paired comparisons into the model.ResultsOf the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex, presence of comorbidity, and tocilizumab, systemic corticosteroid, and plasma therapy use between patients administered with these three different treatment regimens. The mean mortality age of the patients was 71 ± 14.3 years, which was substantially greater than that of the survivors (54.2 ± 15.5 years). Compared with patients administered with LPV/RTV, ICU admission and mortality rates were lower in patients administered with favipiravir. CK-MB, AST, CRP, LDH, and creatinine levels were higher, whereas lymphocyte counts were lower in patients who died. Age, AST, CRP, LDH, and neutrophil counts were higher in patients needing ICU, and eosinophil and lymphocyte counts were significantly lower. Logistic regression analysis showed that favipiravir use independently decreased mortality (p = 0.006).ConclusionThe use of favipiravir was more effective than LPV/RTV in reducing mortality in hospitalized patients with COVID-19.This work is licensed under a Creative Commons Attribution 4.0 International License.

28 keywords...

hide…